Clinical Research & FDA Approval
FDA
Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets
(The Oncologist)
by Martin H. Cohen et al.
v.8 The Oncologist (August 2003): 303-306
Summarizes the efficacy and safety results of clinical trials relevant
to the approval of gefitinib (ZD1839; Iressa) as monotherapy treatment
for patients with locally advanced or metastatic NSCLC after failure of
both platinum-based and docetaxel therapies. [8/03]
ZD1839
(Iressa): What's In It for the Patient?
(The Oncologist)
by Ronald B. Natale and Susan L. Zaretsky
v.7, Suppl.4 The Oncologist (August 2002): 25-30
Provides an overview of ZD1839 (Iressa), the first of a new class
of epidermal growth factor receptor tyrosine kinase inhibitors. Discusses
the results of two phase II trials that have shown that ZD1839 provides
clinically significant symptom relief for many patients with extensively
pretreated advanced NSCLC. Moreover, this improvement in disease-related
symptoms correlated with improved survival and tumor response. ZD1839
also had an acceptable tolerability profile: most drug-related adverse
events were mild and reversible. Some patients also experienced improved
quality of life, particularly those with a partial response or stable
disease. Concludes that ZD1839 offers a new treatment option providing
meaningful symptom relief for many patients with NSCLC. [8/02]
Iressa
& Treatment of Brain Metastases from NSCLC - Recent MEDLINE Abstracts
(PubMed)
Iressa - Clinical Trials
Iressa
- Clinical Trials (ClinicalTrials.gov)
Iressa - Side Effects
Iressa
& Interstitial Pneumonia - Recent MEDLINE Articles (PubMed)
|
